56.00
56.00 (0%)
As of Feb 14, 2025
Belite Bio, Inc [BLTE]
Source:
Company Overview
Belite Bio, Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have significant unmet medical need such as (i) Geographic Atrophy (GA), the late atrophic (“dry”) form of age-related macular degeneration (AMD), and (ii) Stargardt disease type 1 (STGD1).
| Country | United States |
| Headquarters | san diego, california |
| Phone Number | 1-858-246-6240 |
| Industry | manufacturing |
| CEO | Yu-Hsin Lin |
| Website | https://www.ncbi.ie |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | |
| Operating Profit | $-40 |
| Net Income | $-36.1 |
| Net Cash | $-56.5 |
Profit Ratios
| Gross Margin | $0 |
| Operating Margin | |
| Profit as % of Revenues | |
| Profit as % of Assets | -29.3% |
| Profit as % of Stockholder Equity | -24.8% |
Management Effectiveness
| Return on Equity | -24.8% |
| Return on Assets | -23.8% |
| Turnover Ratio | |
| EBITA | $-40 |
Balance Sheet and Cash Flow Measures
| Total Assets | $152.1 |
| Total Liabilities | $6.3 |
| Operating Cash Flow | $-29.2 |
| Investing Cash Flow | $-110.6 |
| Financing Cash Flow | $83.6 |
